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Cord blood platelet rich plasma (CB-PRP) derivatives have been investigated as potential
therapeutic agents for the treatment of diverse conditions including ocular surface
disease and skin ulcers. We have developed processes for the formulation of several
CB-PRP preparations, which have different composition and attributes. Here we describe
the molecular characteristics of these preparations and we make recommendations as
to their most appropriate clinical application based on functional and immunomodulatory
profiles. We show that incubation of adult peripheral blood mononuclear cells (PBMCs)
with all three preparations dramatically reduced the production of INFγ and the
expression of NKG2D and CD107a in NK, NKT, and T cells thus diminishing their
activation, we propose that the likely mechanism is the high levels of soluble NKG2D
ligands present in plasma. Of the three preparations we investigated, CB platelet
lysate (PL) and platelet releaseate (PR) have higher concentrations of trophic and
pro-angiogenic factors, CB platelet poor plasma (PPP) has the lowest concentration of all
analytes measured. Based on these finding we propose that CB-PR is the most suitable
raw material for skin wound patches, while CB-PL and PPP can be used to prepare eye
drops for severe ocular surface pathologies and inflammatory conditions such as corneal
ulcers or severe dry eye disease, respectively.
Keywords: cord blood, platelets rich plasma, plasma, platelets, ocular surface disease, skin ulcer,
immunomodulation
INTRODUCTION
Human platelet rich plasma (PRP) has been recognized as a rich source of trophic factors
(1, 2), which aid healing in several indications including some ocular surface disorders (3, 4),
such as severe dry eye disease and corneal ulcers, skin wounds (5) and orthopedic applications.
Initially, autologous PRP was used to treat corneal injuries (6) but more recently allogeneic
preparations have been favored (7–9). PRP can be obtained readily from both adult peripheral
and cord blood (CB). Comparisons of PRP obtained from these two sources suggest that
they differ both in the type and in the amount of factors they contain (10). These and
other studies argue that CB-PRP has therapeutic advantages over adult PRP as the latter
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contains more pro-inflammatory molecules which can aggravate
certain conditions, while CB-PRP contains higher levels of anti-
inflammatory molecules [reviewed in (11)].
CB-PRP contains soluble molecules of NK Group 2, member
D (NKG2D) ligands (sNKG2DL), which are in part responsible
for NK, NKT, and T cells suppression and may represent
a mechanism of fetomaternal tolerance (12). Further work
elucidated the differential roles of the various types of sNKG2DLs
and revealed soluble unique long 16 binding proteins (sULBP1)
as the most abundant soluble ligand in CB-PRP that directly
downmodulated NK cell cytotoxicity in a dose-dependent
manner (13). Additionally, we showed that polymorphisms
in Major Histocompatibility Complex Class I-related Chain
A (MICA) which encode either valine (Val) or methionine
(Met) at residue 129 affected the ability of soluble MICA
(sMICA) to suppress NK cell function. Met is known to
bind with strong affinity to NKG2D whereas Val has weaker
binding (14).
Depending on the processing protocols used to separate
the PRP from whole blood, a variety of preparations can be
made which have different properties. An initial low speed
centrifugation of whole CB units yields CB-PRP which can
be further processed. CB-PRP contains a variety of growth
factors (GF), cytokines and other immunomodulatory factors
that can act on the proliferation, differentiation and function
of both immune and other cells such as fibroblasts. CB-
PRP also contains albumin, transferrin, fibronectin, fibrinogen,
minerals, adiponectin, vitamin A and E, several fatty acids
and platelets (15), which contribute as trophic factors in
wound healing mechanisms of epithelial cells of the cornea
and its stromal tissue (16). These elements have also been
implicated in cutaneous scarring formation (17). Thus, the
availability through CB banking and the therapeutic benefits
of the factors contained in CB-PRP derived products make
CB an ideal product source for the treatment of a variety
of diseases and inflammatory conditions. These benefits can
be enhanced by processing the PRP both by concentration
of the platelets and their lysis, which releases platelet-derived
growth factor (PDGF), basic fibroblast growth factor (bFGF),
epithelial growth factor (EGF), vascular endothelial growth
factor (VEGF), and transforming growth factor beta (TGFβ)
among others, all of which have been shown to enhance tissue
regeneration (18).
The purpose of this study was to compare the profile
of GFs, cytokine and immune elements of CB-PRP derived
preparations to determine which ones would be best suited
for clinical applications. We formulated, from CB-PRP, three
different preparations: (a) platelet poor plasma (CB-PPP), (b)
platelet concentrate lysate (CB-PL), and (c) platelet concentrate
releaseate (CB-PR).
The concentrations of various GFs, cytokines and soluble
NKG2D ligands, together with their immunomodulatory effects
on Natural Killer (NK) cells and CD8+ T cells were determined
in the different CB-PRP preparations. Taken together, the results
can help us determine the optimal CB-PRP derived preparations




PRP derived samples from individual CB units were obtained
from BioBank (BST). The informed consent for the use of
samples for research was obtained in accordance with the
requirements of the Declaration of Helsinki and local laws at
the time of collection. This study was approved by the BST local
Research Ethics Committees (HCB/2017/0785).
CB Unit Collection
CB units were collected in authorized maternity hospitals. Before
delivery, mothers signed an informed consent for donation that
allows the use of these samples for research and validation
purposes. Qualified health care professionals collected CB units
while placenta was still in utero using validated procedures (19).
The collection bag contains 25mL of citrate phosphate dextrose
(CPD) as anticoagulant.
CB Unit Verification
Full serological and microbiological analysis of the CB units
was carried out to exclude infection. Tests were performed
for the presence of Hepatitis A, B, and C viruses, human
immunodeficiency virus, Treponema Pallidum (Syphilis),
Trypanosoma cruzi (Chagas disease), and cytomegalovirus as
well as aerobic and anaerobic bacterial and fungi (BacTAlert,
Biomerieux, INC. Durham). Quarantine was applied as a
minimum for 2 weeks. Only units, which were non-reactive,
were further processed.
Preparation of CB-PRP Derivatives
Briefly, a total of 20 whole CB (WCB) units were used for
the experiments. Units were treated individually and from each
unit we derived all 3 preparations described. Each unit was
centrifuged at low speed (210 g) for 10min, the supernatant
collected constitutes the PRP. The PRP was then centrifuged at
high speed (2,000 g) for 15min to obtain two fractions, a PPP and
a platelet pellet, whichwas resuspended in PPP to obtain a platelet
concentrate (CB-PC) in range of 800–1,200 × 109 platelets/L in
10 (±5)mL and then stored at−80◦C. CB-PC fraction was frozen
for quarantine. Only microbiology and serology results negative
samples of CBPCwere used for preparation of platelet lysate (CB-
PL) and platelet releaseate (CB-PR). Figure 1 shows a schematic
of the processing of CB to obtain the different preparations tested.
CB-PPP Preparation
The remaining PPP was frozen at −80◦C for future analysis; this
product is CB-PPP.
CB-PL Preparation
CB-PC samples underwent 3 freeze (∼-80◦C)/thaw (∼37◦C)
cycles (20) to lyse platelets and release GFs followed by a
centrifugation step at 5,000 g for 15min. The collected GF rich
supernatant free of intact platelets was subsequently stored at
−80◦C for future use. This CB-PL, diluted with Plasmalyte
(Baxter, USA) (1:1, v:v) is used to prepare CB eye drop
(CBED), which was used in clinical trial [ClinicalTrails.gov ID
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FIGURE 1 | CB-PRP derivatives processing scheme.
NCT03084861]. For this study was used only CB-PL, without
dilution as the active ingredient.
CB-PR Preparation
CB-PC underwent one freeze/thaw cycle (which in our
experience is insufficient to cause major platelet lysis and
allows the storage of this fraction ready for calcium gluconate
activation), the resulting fraction termed platelet releasate was
treated with 10% calcium gluconate (Braun R©, Terrassa, Spain)
(1:10, v:v) and incubated for 1 h at room temperature. This
jellification step forms the basis for the clinical skin patch,
which has been used for clinical trial (ClinicalTrails.gov ID
NCT02389010). For the purpose of the analyte measurement
in this study, the releasate was also treated with 10% calcium
gluconate (as above) but in the presence of heparin at 0.61 IU/mL
to prevent clotting and thus the jellification of the plasma and
trapping GFs, which would have confounded the measurements
of factors in this preparation. After a centrifugation step (5,000 g
for 15min) the supernatant free of intact platelets (checked
by automatic counter-Beckman-Coulter) was used for analyte
measurements or stored at−80◦C until needed.
CB-PRP Derived Products Cytokines and
GF Quantification
CB-PRP preparations of CB-PPP, CB-PL, and CB-PR from
single units were analyzed using magnetic beads of Luminex
kits (R&D Systems, Abingdon, UK) according to manufacturer’s
recommendations, to determine concentration of following
analytes: (plate 1) PDGF AB/BB, EGF, bFGF, VEGF, IL1/6/10,
TNFα; (plate 2) TGFβ1; (plate 3) HGF; (plate 4) MMP2/9;
(plate 5)TIMP1-4.
PBMC Functional Analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood (WB) from consenting, healthy adult male or
female volunteer donors by density-gradient centrifugation using
Lympholyte R©-H solution (Cedarlane, ON, Canada). PBMCs
were then used for co-culture with the various CB-PRP derived
preparations for functional analysis. For assessment of cellular
function of CD3- CD56bright/dimNK cells, CD3+CD56+NKT
cell and CD3+ CD56– T cells, healthy adult donor PBMCs
were plated in RPMI (Lonza, Slough, UK) containing 10%
heat-inactivated fetal calf serum (FCS) supplemented with 1%
penicillin and streptomycin (complete media) and containing
human IL-2. Test cultures using CB-PRP preparations: CB-
PPP, CB-PL or CB-PR were diluted with an equal volume
of complete media containing 200 IU IL-2 per well (200 µl
volume) in 96-well U-bottom plates. Results were normalized
against PBMCs cultured with complete media containing 200
IU IL-2 per well and expressed as percentage of maximum
expression (for measurement of NKG2D, CD107a or IFN-
γ expression). All cultures were incubated at 37◦C with 5%
CO2 for 48 h before Phorbol 12-myristate 13-acetate (PMA)
and ionomycin stimulation. Duplicate cultures were carried out
for each experiment without PMA and ionomycin stimulation
to assess levels of NKG2D and baseline CD107a expression.
NKG2D expression on the relevant cells was determined using
the unstimulated cultures and CD107a background levels in
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unstimulated cultures were subtracted from the values obtained
for equivalent stimulated cells. Three independent experiments
were carried out using four different, healthy PBMC donors,
each tested with CB-PPP, CB-PL, CB-PR, or media only and data
points represent donor means for each replicate test sample.
Flow Cytometry
Briefly, cells were labeled with fluorochrome-conjugated
antibodies in Phosphate-buffered saline (PBS) with Bovine
Serum Albumin (BSA) (0.5%) for 10min at 4◦C. Antibodies
(BD Biosciences, Oxford, UK) were as follows: CD3 (SK7),
CD56 (B159), CD107a (HA4A3), NKG2D (BAT221, Miltenyi
Biotec, Bisley, UK). Viability was assessed using Annexin V and
7-AAD. For quantitation of CD107a, cells were re-suspended in
complete media containing 100 ng/ml PMA, 1 µg ionomycin
and 0.1% 2-mercaptoethanol (stimulated) or complete media
with 0.1% 2-mercaptoethanol (non-stimulated) for 2 h at 37◦C.
Fluorescence minus one (FMO) controls (where samples are
stained sequentially with all antibodies except one) were used
to set gates. Acquisition was performed using a Fortessa II
flow cytometer (BD Biosciences, Oxford, UK) and analysis
was carried out using FlowJo version 10.5.0 (Tree Star Inc.,
OR, USA). The gating strategy used for analysis of lymphocyte
subtypes was performed as described in our previously study
(12) and is shown in Supplementary Figure S1.
Soluble NKG2DL and IFN-γ Detection and
Quantification Assays
Soluble MICA/B (DY1300/DY1599) and ULBP1 (DY1380) were
quantified in CB-PRP derivatives directly and IFN-γ (DY285)
was measured in PBMC stimulated supernatants using Duoset
ELISA kits (R&D Systems, Abingdon, UK), according to
manufacturer’s instructions.
MICA-129 (Valine or Methionine) SNP
Genotyping
Genomic DNA for MICA genotyping was obtained from WCB
using QIAamp R© DNA blood minikit (Qiagen, GmbH, Hilden,
Germany). The SNP rs1051792 (G/A) causing substitution of Val
(G) forMet (A) at position 129 of the MICA gene was genotyped
using a TaqMan R© assay (Applied Biosystems, Foster City, CA,
USA). PCR amplification conditions were as recommended by
the manufacturer and reactions contained the forward primer
5′-GCTCTTCCTCTCCCAAAACCT-3′ and reverse primer 5′-
CGTTCATGGCCAAGGTCTGA-3′ and the two allele-specific
dye labeled probes FAM-5′-AATGGACAGTGCCCC-3′ and
VIC-5′-AATGGACAATGCCCC-3′. Results were obtained and
interpreted using the CF96 real-time PCR system (Biorad,
Hercules, CA, USA). Confirmatory typing was performed using
DNA extracted fromWCB and polymerase chain reaction (PCR)
amplification and sequencing of exon 3 of the MICA gene.
Results were used to determine the presence of “A,” “G” or both
encoding Met or Val at residue 129 (ATG or GTG, respectively).
Exons 2–6 of the MICA gene were amplified as previously
described (21) using a forward primer located in intron 1
(5′- CACCTGTGATTTCCTCTTCCCCAGAGC-3′) and reverse
primer in the 3′ untranslated region (5′-CTAACAATTTGC
AGCMTCCAACAAC-3′). Cycle sequencing was performed
using standard protocols and exon 3 forward sequencing primer
(5′- CCCTGGGCTGAGTTCCTC-3′) and reverse sequencing
primer (5′- ATAGCACAGGGAGGGTTT-3′).
Statistical Analysis
Results are shown as mean with standard error of the mean
(SEM) and were evaluated using Graphpad Prism 8 (Graphpad
Software, CA, USA. Datasets were analyzed using both paired and
unpaired non-parametric statistical analysis as the sample size is
too small to assume normal distributions. As we had 3 categories
of sample, we used Friedmans’s test for the paired comparisons
and a Kruskal-Wallis for the unpaired analysis. Significance levels
are indicated as p < 0.05 (∗), p < 0.01 (∗∗), p < 0.001 (∗∗∗),
and p < 0.0001 (∗∗∗∗), unless the exact p-value is given. For
comparisons between genotypes only we used Mann-Whitney.
RESULTS
Comparison of Cytokine and GF
Concentration Among the Different
Preparations of CB-PRP Derivatives
The prepared CB-PC units contained 1,004 ± 76 × 109 platelets
(PLT)/L (n = 10) and were within the standard range of 800–
1,200× 109 PLT/L, which was used to prepare CB-PL andCB-PR.
The levels of trophic and wound healing factors (group I), pro-
angiogenic molecules (group II), pro-inflammatory (group III.A)
and anti-inflammatory (group III.B) GFs and cytokines for all
three preparations were analyzed and compared, the results are
shown in Table 1, Figure 2, we have included statistical analysis
of results both for paired and unpaired samples on the table, but
the graph shows only significance for the paired samples. For
comparative purposes the levels in tears of some of these factors
are as follows: EGF (200–3,000 pg/mL), TGFβ (2–10 ng/mL),
HGF (200–500 pg/mL), VEGF (2–19 pg/mL), PDGF (90–1,700
pg/mL) (3). In CB-PL preparations the concentration of most
factors tested was higher than that observed in CB-PPP, however
this did not reach significance in HGF, MMP-2, TIMP-1, 2, and
4 or IL6 and was lower for MMP-9. There were no statistically
significant differences in concentration in any of the analytes
examined between CB-PR and CB-PL, except for HGF, MMP-
2, and TIMP-2 and 4, which were higher in CB-PL (Table 1,
Figure 2).
As expected, for processed CB-PPP samples, that had 8 ±
3 × 109 PLT/L in 24 ± 4mL (n = 10), all measured analytes
had lower concentrations, with the exception for HGF, TIMP-
2 and 4 which were no different and MMP-2 and 9, which
were higher in CB-PPP than in CB-PR (Table 1). Pro-angiogenic
factors showed low concentrations, except for MMP-9. Both
pro and anti-inflammatory cytokines have significantly higher
concentration in CB-PL than CB-PPP, but are similar between
CB-PL and CB-PR (Table 1, Figure 2). In adult serum the
concentrations of these factors are as follows: EGF (500–1,000
pg/mL), TGFβ (6–50 ng/mL), HGF (100–1,000 pg/mL), VEGF
(1,000–5,000 pg/mL), PDGF (30–100 ng/mL) (3). While levels of
EGF, VEGF, HGF are comparable between CB-PL, CB-PR, and
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Group I (trophic and wound healing factors)
pg/mL
EGF CB-PPP 93.5 ± 5 0.0004 0.0110 >0.9999 0.0002 0.008 >0.9999
CB-PL 858 ± 66
CB-PR 800.6 ± 54
bFGF CB-PPP 179.5 ± 5 0.0004 0.0110 0.9999 0.0001 0.0011 >0.9999
CB-PL 348 ± 26
CB-PR 310 ± 21
HGF CB-PPP 1446 ± 204 0.0553 0.29669 0.0002 >0.9999 0.6702 0.1399
CB-PL 1676 ± 227
CB-PR 1127 ± 116
TGF-β1 CB-PPP 8767 ± 929 0.0002 0.1365 0.1365 0.0003 0.0126 0.8665
CB-PL 58646 ± 3553
CB-PR 49461 ± 3949
Group II (pro-angiogenic factors)
pg/mL
VEGF CB-PPP 329 ± 17 <0.0001 0.0760 0.0760 <0.0001 0.0038 0.7279
CB-PL 1046 ± 367
CB-PR 798 ± 90
PDGF
AB/BB
CB-PPP 3388 ± 535.5 <0.0001 0.1017 0.1017 <0.0001 0.0569 0.0447
CB-PL 37267 ± 1817
CB-PR 10276 ± 752
ng/mL
MMP-2 CB-PPP 170 ± 8 >0.9999 0.0012 0.0140 >0.9999 0.0905 0.1607
CB-PL 153 ± 9
CB-PR 140 ± 7.7
MMP-9 CB-PPP 101 ± 12 0.0286 0.0005 0.7158 >0.9999 0.8959 >0.9999
CB-PL 88 ± 12
CB-PR 83.4 ± 13
TIMP-1 CB-PPP 157 ± 12 0.0733 0.0005 0.4008 0.0100 0.0003 >0.9999
CB-PL 332 ± 18
CB-PR 372 ± 11
TIMP-2 CB-PPP 48 ± 2.6 0.2969 0.0553 0.0002 0.8156 0.0720 0.0024
CB-PL 48.7 ± 2
CB-PR 38.8 ± 2.5
TIMP-3 CB-PPP 1.1 ± 0.01 0.0029 0.0065 >0.9999 0.0019 0.0033 >0.9999
CB-PL 2.8 ± 0.2
CB-PR 3.0 ± 0.3
TIMP-4 CB-PPP 1.8 ± 0.2 0.2969 0.0553 0.0002 0.8156 0.7047 0.0667
CB-PL 2.0 ± 0.2
CB-PR 1.5 ± 0.2
Group III.A (pro-inflammatory GFs and cytokines)
pg/mL
IL-6 CB-PPP 77 ± 10 0.0140 >0.9999 0.1017 0.0778 >0.9999 0.4621
CB-PL 98 ± 6
CB-PR 82 ± 5
(Continued)
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IL-1α CB-PPP 40.5 ± 1.0 <0.0001 0.1017 0.1017 <0.0001 0.0081 0.6702
CB-PL 88 ± 8
CB-PR 69 ± 4
TNF-α CB-PPP 103 ± 1.6 0.0024 0.0024 >0.9999 0.0008 0.0009 >0.9999
CB-PL 123.6 ± 4
CB-PR 122 ± 2
Group III.B (anti-inflammatory cytokines)
pg/mL
IL-10 CB-PPP 43.5 ± 0.8 0.0004 0.0110 >0.9999 <0.0001 0.0020 >0.9999
CB-PL 72 ± 8
CB-PR 63.8 ± 3
Non-parametric comparison test. n = 10/product type.
adult serum, the concentration of PDGF is lower in CB-PR. TGFβ
is slightly higher in CB-PC derived products and comparable to
adult serum levels in CB-PPP samples.
Effect of CB-PRP Preparations on Donor
Cell Viability
After measuring the levels of GFs and other factors, we
investigated the effect of the PRP derivatives preparations on
immune cells, specifically on NK cells. We and others have
established that the immunomodulatory effects of plasma leading
to suppression of NK cells are exerted through both the
high concentration of TGFβ and NKG2D engagement with
sNKG2DLs. Therefore, we examined the effects of the different
preparations on the phenotype and activity of NK, NKT, and
T cells.
Initially we examined the effect of incubation of PBMCs in
the presence of the different preparations to ensure they had
no toxic effects and viability was comparable. We incubated the
cells in standard cell culture conditions, with 50% solution of
each PRP preparation, diluted with complete media containing
IL-2. We then determined the percentage of live lymphocytes
by gating CD3-CD56 bright/dim NK cells, CD3+ CD56+ NKT
cells and CD3+ CD56– T cells cultured with each of the CB-
PRP preparations. The results, shown in Figure 3. show a general
improvement in viability when cells were cultured with CB-PRP-
supplemented media compared to media only. For all cell types
investigated, viability was significantly improved in the presence
of CB-PR compared to media only. While the presence of CB-PL
was only significantly better compared to media alone in CD3–
CD56 bright NK cells, CB-PPP was significantly better only in
CD3-DC56 dim NK cells.
The viability of CD3– CD56 bright NK cells was not
significantly different between cells grown in CB-PR or CB-PL
when samples were compared either paired or unpaired. Growing
them in the presence of CB-PL or CB-PR increased the viability
significantly compared to CB-PPP, again regardless of samples
being paired or unpaired. For CD3– CD56 dim NK cells the
presence of CB-PR improved viability significantly compared
to CB-PPP and CB-PL again regardless of sample pairing, and
there was no significant difference between CB-PPP and CB-
PL in these cells. The viability of CD3+ CD56+ NKT was
highest in cells grown in CB-PR but the difference was only
slightly significant between CB-PR and CB-PL when samples
were analyzed paired. For CD3+CD56– T cells, again CB-PR is
significantly better than CB-PL, but no different than CB-PPP
whether samples are analyzed paired or unpaired.
Overall, incubation of PBMCs in the presence of all three
CB-PRP preparations had a beneficial effect on viability and no
detrimental or toxic effect.
Incubation With CB-PPP, CB-PL, and
CB-PR Shows Differential Reduction in
NKG2D Expression
Generally, incubation of peripheral blood CD3– CD56 dim and
bright NK cells, CD3+ CD56+ NKT cells and CD3+ CD56– T
cells with CB-PRP derivatives resulted in reduced expression of
NKG2D relative to media only (Figure 4). Significant differences
were observed between the different preparations of CB-PRP
with all cell types, with CB-PL reducing NKG2D expression
the most. While incubation with CB-PPP only reduced NKG2D
expression to 94.7% ± 0.25 of maximal expression in CD3–
CD56 dim NK cells, CB-PR reduced it to 78.6% ± 2.05 (p =
0.0052) and CB-PL to 77.04% ± 2.57 (p = 0.0010). Similar
NKG2D expression patterns were seen in CD3– CD56 bright
NK cells after incubation with the 3 preparations. Analysis
of CD3+ CD56+ NKT cells showed a similar reduction in
NKG2D expression after treatment with both CB-PL and CB-
PR (49.3% ± 2.3% and 54.7% ± 1.5%, respectively) which was
significantly more pronounced than culture with CB-PPP (p =
0.0004 and p = 0.0110, respectively in paired analysis). A similar
profile to CD3+ CD56+ NKT cells was observed for CD3+
CD56– T cells, though the overall reduction in expression was
less dramatic.
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FIGURE 2 | (A) Trophic and wound healing factors in CB-PRP preparations in pg/mL, growth factors analyzed were EGF, bFGF, HGF, and TGF-β1. (B–D)
Concentration of the angiogeneic group of factors in CB-PRP derived preparations. Results show concentration in pg/mL and ng/mL of each factor. The analytes
measured were (B) VEGF and PDGF in pg/mL; (C) MMP-2 and MMP-9 in ng/mL; (D) TIMP1-4 in ng/mL. (E) Concentration of inflammatory and anti-inflammatory
cytokine group of analytes in CB-PRP preparations. Data points represent concentration mean of IL-1α, IL-6, and TNF-α pro-inflammatory and IL-10 anti-inflammatory
cytokines. CB-PRP preparations investigated were, cord blood platelet poor plasma (CB-PPP; n = 10), cord blood platelet lysate (CB-PL; n = 10) or cord blood
platelet releasate (CB-PR; n = 10). Each sample was measured in duplicate in two separate experiments. Data points represent concentration mean. Statistical
analysis was performed using non-parametric one-way ANOVA (Kruskal-Wallis test with Dunn’s post-hoc test for unpaired samples and Friedman’s for paired
samples). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Incubation With CB-PL, CB-PPP, and
CB-PR Reduces Expression of CD107a and
IFN-γ
Incubation of all cell types examined with CB-PL resulted not
only in a significant reduction in the expression of NKG2D,
but also in a dramatic, and statistically significant, reduction in
the expression of CD107a indicating a reduction in activation
potential as shown in Figure 5. For example, percentage of
maximum expression of CD107a in CD3- CD56bri NK cells
incubated with CB-PL was 34.2% ± 3.4 SEM compared to
72.8% ± 4.01 SEM with CB-PPP (p = 0.002) and 41.4% ±
3.81 SEM with CB-PR (p = 0.539). Similar differences were
seen in CD3– CD56 dim NK cells and CD3+ CD56+ NKT
cells. Compared with NK and NKT cells, a smaller reduction
in CD107a expression was seen in CD3+ CD56– T cells and
there was no significant difference between CB-PR and CB-
PL. However, CD107a expression, in the presence of both CB-
PL (52.9% ± 4.14) and CB-PR (54.48 ± 3.8), was significantly
reduced compared to incubation with CB-PPP (83.3% ± 2.2)
(p = 0.0024). We measured the total IFN-γ produced after
stimulation of cultures following the incubation period and
results are shown in Figure 6. All CB-PRP preparations resulted
in reduced IFN-γ production compared to complete media only,
though there were no significant differences between CB-PR
and CB-PL, treatment with both these preparations resulted in
significantly less IFN-γ production compared to CB-PPP.
CB-PRP Preparations CB-PL, CB-PPP, and
CB-PR Contain sNKG2DLs
We previously reported that CB plasma contains soluble
NKG2DLs such a sMICA, sMICB, and sULBP1 (12, 22). Using
ELISA, we measured the concentration of these ligands in the
different preparations of CB-PRP. For this analysis we used two
sets of preparations for CB-PL and CB-PR with a total of 20
and 19 samples, respectively. One set of CB-PPP was too dilute
for the limit of detection of the assay, therefore only 10 samples
were utilized.We found that sMICA ligands were present in most
samples of CB-PPP, CB-PL, and CB-PR and all contained sMICB
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FIGURE 3 | Viability of CD3- CD56 dim, CD3- CD56 bright NK cells, CD3+ CD56+ NKT cells, and CD3+ CD56- T cells from adult donor PBMCs (n = 3) after
incubation with cord blood plasma preparations or complete media only. Results show percentage of live cells (Annexin V negative, 7-AAD negative) for each cell type.
Cord blood plasma preparations investigated were cord blood platelet poor plasma (CB-PPP; n = 10), cord blood platelet lysate (CB-PL; n = 10), or cord blood
platelet releasate (CB-PR; n = 10). PBMCs were incubated with each preparation diluted 50:50 with media and supplemented with IL-2, or with complete media and
IL-2 only for 48 h prior to antibody staining and flow cytometry analysis. Each experiment was repeated with four different PBMC donors and data points represent
donor means. Statistical analysis was performed using non-parametric one-way ANOVA (Kruskal-Wallis test with Dunn’s post-hoc test for unpaired samples and
Friedman’s for paired samples). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
and sULBP1 (Figure 7A). There was no significant difference
in levels of sMICA or sMICB among the different CB-PRP
preparations but significantly more sULBP1 could be detected in
CB-PL (3.85 ng/ml ± 0.20) compared to CB-PPP (2.62 ng/ml ±
0.35) (p= 0.0058).
MICA Polymorphisms and Their Effects on
IFNγ Production
The MICA polymorphism encoding either valine (Val; V) or
methionine (Met; M) at residue 129 of the MICA protein is
thought to influence functional differences in NK cell activation
(14). We categorized CB-PRP preparations (CB-PL, CB-PPP,
and CB-PR) as either Val homozygous (V/V) or homozygous
and heterozygous samples containing Met (M/M and V/M) and
examined the amount of IFN-γ produced by NK cells after
PMA and ionomycin stimulation compared to media alone
(Figure 7B). As expected per previous results the production
of IFNγ is reduced by the presence of the CB-PRP derived
preparations (∼60%), but the reduction is not uniform across
preparations (incubation with CB-PR leads to ∼50% less
INFγ for example) but it is not significantly different within
preparations for the different genotypes. In agreement with our
previous study, we did detect a difference in reduction of IFN-
γ according to genotype with CB-PPP. Samples typed as V
homozygous showed less of a reduction in production of IFN-
γ (mean 52% ± 2.4 SEM) compared to M homozygous and
V/M heterozygous samples (mean 42% ± 1.5 SEM) and was
statistically significant (p = 0.0074). Overall, 50% of samples
tested were V/V and 50%M/M or M/V genotype.
DISCUSSION
In this study we have assessed and compared the properties of
3 different CB-PRP preparations, CB-PPP, CB-PL and CB-PR.
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FIGURE 4 | Expression of NKG2D on NK, NKT and T cells from healthy donors is reduced by incubation with, CB-PPP, CB-PL, and CB-PR. Data represents analysis
of CD3– CD56 dim, CD3– CD56 bright NK cells, CD3+ CD56+ NKT cells and CD3+ CD56– T cells in adult donor PBMCs (n = 4) after incubation with CB-PRP
preparations or complete media only. Results show percentage of maximum expression relative to complete media for each cell type from unstimulated cultures.
CB-PRP preparations investigated were cord blood platelet poor plasma (CB-PPP; n = 10), cord blood platelet lysate (CB-PL; n = 10), or cord blood platelet
releasate (CB-PR; n = 10). PBMCs were incubated with each preparation diluted 50:50 with media and supplemented with IL-2, or with complete media and IL-2 only
for 48 h prior to antibody staining and flow cytometry analysis. Each experiment was repeated with four different PBMC donors and data points represent donor
means. Statistical analysis was performed using non-parametric one-way ANOVA (Kruskal-Wallis test with Dunn’s post-hoc test for unpaired samples and Friedman’s
for paired samples). *p < 0.05, **p < 0.01, ***p < 0.001.
We measured the concentrations of various factors which are
thought to contribute to the activity of CB-PRP. We found that
as expected the CB-PPP preparation had lower concentrations
of most analytes, while there was less differences between
CB-PL and CB-PR. In general, the concentrations of the key
analytes were higher in CB-PRP preparations than in tears
and comparable to those in adult serum. This is similar to
other reported studies (23, 24), though we measured additional,
previously not reported analytes.
Further we looked at the immunomodulatory properties of the
3 preparations, by investigating their effects on the activation of
NK, NKT, and T cells. We found that all 3 preparations reduced
the expression of activation markers NKG2D and CD107a in all
cell types investigated to different degrees and further they also
decreased the expression of INFγ in NK cells. As we used the
same unit to make all three preparations, and the paired and
unpaired analysis give almost identical results, it is most likely the
effects are due to the PRP preparation and only some of the effect
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FIGURE 5 | Expression of CD107a after PMA and ionomycin stimulation on NK, NKT, and T cells from healthy donors is reduced by incubation with, CB-PPP, CB-PL,
and CB-PR. Data represents analysis of CD3– CD56 dim, CD3– CD56 bright NK cells, CD3+ CD56+ NKT cells and CD3+ CD56– T cells in adult donor PBMCs (n =
4) after incubation with CB-PRP derived samples or complete media only. Results show percentage of maximum expression relative to complete media for each cell
type following 2 h stimulation with PMA and ionomycin. CB-PRP preparations investigated were cord blood platelet poor plasma (CB-PPP; n = 10), cord blood
platelet lysate (CB-PL; n = 10), or cord blood platelet releasate (CB-PR; n = 10). PBMCs were incubated with each preparation diluted 50:50 with media and
supplemented with IL-2, or with complete media and IL-2 only for 48 h prior to antibody staining and flow cytometry analysis. Each experiment was repeated with four
different PBMC donors and data points represent donor means. Statistical analysis was performed using non-parametric one-way ANOVA (Kruskal-Wallis test with
Dunn’s post-hoc test for unpaired samples and Friedman’s for paired samples). *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001.
is due to individual variations between individuals. As we have
reported previously, we believe this reduction is caused by the
presence of soluble NKG2D ligands (MICA, MICB and ULBP1)
in the CB-PRP preparations, but it would be prudent to have
a larger sample size to confirm this. Studies in tumor biology
do corroborate this idea, as soluble NKG2D ligands produced
by tumor cells have been reported to downregulate NK cell
responses (25, 26).
To understand better the properties of these PRP preparations
and the processing methodology, it would be important to
measure the concentrations of the GFs at different stages
during the processing and see how the different steps affect the
final product.
The mechanism of action of CB-PRP in terms of
immunomodulation has been investigated by us and others
(12, 22). The anti-inflammatory molecule transforming growth
factor beta (TGFβ), is an obvious candidate to exert such a
function as it is known to be present in fairly high levels in
PRP (27–29). Some studies have looked at the effect of TGFβ
on the induction of T-regulatory (Tregs) cells as a plausible
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FIGURE 6 | IFN-γ production by PBMCs from healthy donors is reduced by
incubation with CB-PPP, CB-PL and CB-PR samples. Results show
percentage of maximum IFN-γ expression in culture supernatants relative to
complete media following 2 h stimulation with PMA and ionomycin. CB-PRP
preparations investigated were cord blood platelet poor plasma (CB-PPP; n =
10), cord blood platelet lysate (CB-PL; n = 10), or cord blood platelet releasate
(CB-PR; n = 10). PBMCs were incubated with each preparation diluted 50:50
with media and supplemented with IL-2, or with complete media and IL-2 only
for 48 h prior to antibody staining and flow cytometry analysis. Each
experiment was repeated with four different PBMC donors and data points
represent donor means. Statistical analysis was performed using
non-parametric one-way ANOVA (Kruskal-Wallis test with Dunn’s post-hoc
test for unpaired samples and Friedman’s for paired samples). No significant
differences between the different CB-PRP preparations were found.
*p < 0.05, ***p < 0.001.
mechanism to explain the overall anti-inflammatory properties
of PRP preparations (7). In contrast, in our previous studies we
were able to demonstrate that CB-PRP preparations contain
soluble molecules that act as ligands for NK cell receptors
and result in reduction of NK cell activation potential (22).
These soluble molecules, which have an activating role when
expressed on the cell surface, interact with NKG2D and directly
down-modulate cytotoxicity of cells bearing this receptor in a
dose-dependent manner, independent of a similar effect exerted
by TGFβ (12). Further work delineating the differential roles
of the various types of NKG2D ligands (NKG2DLs) revealed
that soluble ULBP1 (sULBP1) was the most abundant ligand in
CB-PRP. Furthermore, we also found that a second NKG2DL
termed MICA, also supressed NK function, but this ability was
affected by a genetic polymorphism in theMICA gene itself (12).
A dimorphism in MICA gives rise to two possible variants of
the protein with either a methionine (Met) or a valine (Val) at
residue 129. This difference has been found to have functional
consequences, with the affinity for the receptor being higher
on the Met containing protein (14). Indeed, investigations
found that PRP preparations from donors who had at least
one Met allele were able to down regulate the expression of
NKG2D, CD107a, and INFγ in NK cells significantly more than
PRP preparations form Val homozygote donors, revealing a
functional difference affecting the anti-inflammatory potential of
sMICA variants (12).
The use of PRP as a treatment for eye (9) and skin lesions
(30) has been established for some time. Though initial studies
were carried out mainly on autologous PRP preparations,
as a means of avoiding transmission of pathogens, the use
of allogeneic PRP has been favored in recent years (9, 31).
The use of allogeneic PRP has several advantages, and it
offers a means of standardizing the preparation and quality
control to make dosing regimens more accurate. Amongst
the sources of PRP, CB has been studied closely in the
last decade or so, as it has all of the advantages of other
allogeneic sources, with the extra advantages of being essentially
a waste by product which requires very little extra effort to
prepare; having special properties and being less likely to have
unexpected transmissible viral pathogens, asmothers are checked
during pregnancy.
Currently we are using CB-PRP preparations on two separate
clinical trials for two indications: an eye drop treatment for
Neurotrophic Keratopathy (NCT03084861) and a gel patch
for diabetic foot ulcers (NCT02389010). However, there is a
need to establish the likely differences in preparations and
how the biochemical content and functional attributes of each
preparation may affect their use. We propose that for skin
ulcers, the most appropriate preparation would be platelet
releasate (PR) in gel form (CB-PG), where the GFs content is
released gradually (32). This contains the highest concentrations
of both angiogenic as well as trophic and wound healing
factors and the lowest concentration of inflammatory molecules.
For skin regeneration several phases are required, first there
is a vasoconstriction and platelet aggregation phase to stop
bleeding, followed by an inflammatory phase which recruits
several cells (mainly neutrophils) into the site followed by
a proliferative phase where there is new tissue formation
(33). The second phase requires pro-inflammatory molecules
such as TNFα and INFγ, as well as factors that promote
collagen degradation, followed by a re-epithelialisation phase
where fibroblasts are recruited to the site and with the help
of growth factors induce the multiplication of this fibroblast,
which in turn deposit new collagen. In chronic wounds there
is a clear disruption to this process therefore providing these
factors exogenously should have a positive effect. Consequently,
preparations with high levels of TNFα, for example, which
increase inflammation, as well as metalloproteinases and their
inhibitors, such as the MMPs and TIMPs, which degrade
collagen, should aid in the induction of the wound healing
cascade (34). High levels of bFGF and EGF consolidate the
effect by promoting fibroblast proliferation. The necessary
neo vascularisation is also promoted by VEGF, though the
levels of this factor are modest in the CB-PR preparation.
Importantly the CB-PR preparation reduces the expression of
NGK2D activating receptor as well as CD107a in NK cells only
modestly, thus the necessary immune cell activation and IFNγ
production is not blocked by this preparation. Previous work
using platelet lysate preparations in in vitro models of wound
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FIGURE 7 | CB-PRP preparations (CB-PPP, CB-PL, and CB-PR) contain immunosuppressive soluble NKG2D ligands. (A) ELISA analysis of soluble NKG2D ligand
content (sMICA, sMICB, and sULBP1) in CB-PPP (n = 10), CB-PL (n = 20), and CB-PR (n = 19) revealed similar quantities of sMICA and sMICB. Significantly higher
concentration of sULBP1 was found in CB-PL compared with CB-PPP. (B) MICA genotyping was performed with DNA obtained from whole CB used to prepare
CB-PL (n = 20), CB-PR (n = 19), and CB-PPP (n = 12). MICA-129 valine homozygotes (V/V) were compared with heterozygote and homozygote MICA-129
methionine genotypes (V/M or M/M) for each preparation. Statistical analysis was performed using non-parametric one-way ANOVA (Kruskal-Wallis test with Dunn’s
post-hoc test) or Mann Whitney test. **p < 0.01.
healing demonstrated that the combination of factors present
in platelet lysates was able to promote wound healing in a
dose dependent manner (35). CB-PC derivatives (lysate and
releasate) are rich in GFs, and are attractive sources for many
clinical applications in degenerative conditions, such as joint and
cartilage pathologies (36, 37), where injection of this product can
be beneficial.
For the treatment of ocular conditions, preparations need
to be appropriate to the indication being treated. On the one
hand, ocular ulcers and other conditions that have damaged
the ocular surface where regeneration is required need special
preparations (38). These should contain sufficient quantities of
EGF, bFGF, and a certain quantity of inflammatory cytokines
to activate the regenerative process. However, they must not
promote the excessive proliferation of fibroblasts leading to
scarring, as it would impair the function of the cornea. The CB-
PL preparation has moderately high levels of EGF, bFGF, HGF,
PDGF, and VEGF and fairly high levels of TGFβ (compared
to CB-PPP and CB-PR), mostly in line with those found
in natural tears, except for VEGF which is much higher in
PL. The CB-PL preparation has a dramatic effect on NK,
NKT and CD3 T-cells. It reduces the expression of both
NKG2D and CD107a substantially indicating a reduction on
the activation potential of these cells, thus likely reducing
overall inflammation and disease progression but without
compromising viability.
For ocular diseases where the corneal surface is not yet
compromised, such as dry-eye disease, which is usually caused by
a deficiency of the lacrimal functional unit and is accompanied
by ocular surface inflammation and irritation due to lack
of lubrication (39), the CB-PPP preparation may offer an
optimal topic treatment, though here we analyzed the raw
material, the topical eye drops used for clinical application
are diluted in Plasmalyte, which may dilute the fibrinogen
and the pro-thrombin present in the CB-PRP avoiding their
possible negative effects. So far, studies have not shown any
safety issues caused by the presence of fibrinogen which is
present in autologous PRP preparations too (40, 41), however,
further studies are necessary to measure this more accurately.
This preparation contains low levels of pro-angiogenic and
wound healing factors, it also reduces the activation of NKT
cells by about 50%, which may arrest the progression of
disease caused by the recruitment of Th17 cells. Previous
studies in animal models of severe dry eye disease, showed
that activated NK and NKT cells up-regulated IL-6 and IL-23
and created an environment where dendritic cells could skew
T cell activation to a more pathogenic Th17 phenotype (42).
In the absence of NK and NKT cells, disease progression was
less severe (43), as no pathogenic Th17 cells were activated
(42). Additionally, in the presence of CB-PRP derivatives
preparations there is a substantial reduction (∼50%) in the
production of INFγ by immune cells, which would otherwise
contribute to the inflammatory process. The CB-PPP preparation
contains the lowest levels of the pro-inflammatory cytokines
IL-6, IL-1α, and TNFα, and substantial amounts of soluble
NKG2D ligands (ULBP1, MICA, and MICB), making it ideal
to treat conditions where inflammation has a major role in
disease progression.
In conclusion, CB has unique properties and can be used as
a source of plasma and platelet to formulate preparations for
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regenerative medicine, that can be used for the topical treatment
of several eye conditions that affect the ocular surface, such as
severe dry eye disease, corneal ulcers and burns. Furthermore,
these preparations could also serve as an optimal adjuvant to help
in skin wound healing and for articular regenerative processes.
Through differential processing of CB-PRP production, we have
formulated three blood derived preparations which have different
and interesting biochemical and immunomodulatory properties
which can be investigated in translational applications. Further
work in evaluating the safety and efficacy of these preparations
must now be undertaken.
Additionally, future studies should include: (a) in vivo safety
and efficacy studies in models of corneal and skin wounds. (b)
the assessment of vitamin A concentration on final preparations,
as it is known to be light sensitive (44), but an essential ingredient
in eye drop preparations and (c) the effects of the preparations on
the immune response in general.
DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the
article/Supplementary Material.
ETHICS STATEMENT
Plasma samples from individual CB units were obtained from
BioBank (BST). The informed consent for the use of samples
for research was obtained in accordance with the requirements
of the Declaration of Helsinki and local laws at the time of
collection. This study was approved by the BST local Research
Ethics Committees (HCB/2017/0785).
AUTHOR CONTRIBUTIONS
DS and SC designed, carried out experiments, and wrote
the manuscript. DH analyzed results, designed, and
wrote manuscript. RC-M design study, analyzed results,
and wrote manuscript. SQ, LR, and AM designed study and
reviewed the manuscript.
FUNDING
This Project was supported by a competitive internal grant
of Banc de Sang i Teixits (Ref I. 2017.036). SC, DH,
and AM receive funding from Anthony Nolan (Charity No.
803716/SCO38827).
ACKNOWLEDGMENTS
Thanks to Banc de Sang e Teixit and Anthony Nolan Research
Institute laboratories staff. Thanks to Ms Pauline Dodi for her
help in initial phases of manuscript.
SUPPLEMENTARY MATERIAL




1. Parazzi V, Lazzari L, Rebulla P. Platelet gel from cord blood:
a novel tool for tissue engineering. Platelets. (2010) 21:549–
54. doi: 10.3109/09537104.2010.514626
2. Parazzi V, Lavazza C, Boldrin V, Montelatici E, Pallotti F, Marconi
M, et al. Extensive characterization of platelet gel releasate from
cord blood in regenerative medicine. Cell Transplant. (2015)
24:2573–84. doi: 10.3727/096368915X687471
3. Drew VJ, Tseng C-L, Seghatchian J, Burnouf T. Reflections on dry eye
syndrome treatment: therapeutic role of blood products. Front Med. (2018)
5:33. doi: 10.3389/fmed.2018.00033
4. Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, Fernandez-Vega Cueto
L, Anitua E, Begoña L, et al. Treatment of patients with neurotrophic
keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret)
eye-drops. Int Ophthalmol. (2018) 38:1193–204. doi: 10.1007/s10792-01
7-0582-7
5. Martinez-Zapata M, Martí-Carvajal A, Solà I, Expósito J, Bolíbar I, Rodríguez
L, et al. Autologous platelet-rich plasma for treating chronic wounds (Review)
summary of findings for the main comparison. Cochrane Database Syst Rev.
(2016) 25:CD006899. doi: 10.1002/14651858.CD006899.pub3
6. Ralph RA, Doane MG, Dohlman CH. Clinical experience with
a mobile ocular perfusion pump. JAMA Ophthalmol. (1975)
93:1039–43. doi: 10.1001/archopht.1975.01010020815015
7. Stenwall PA, Bergström M, Seiron P, Sellberg F, Olsson T, Knutson F, et al.
Improving the anti-inflammatory effect of serum eye drops using allogeneic
serum permissive for regulatory T cell induction. Acta Ophthalmol. (2015)
93:654–7. doi: 10.1111/aos.12801
8. Rebulla P, Pupella S, Santodirocco M, Greppi N, Villanova I, Buzzi M, et al.
Multicentre standardisation of a clinical grade procedure for the preparation
of allogeneic platelet concentrates from umbilical cord blood. Blood Transfus.
(2016) 14:73–9. doi: 10.2450/2015.0122-1
9. Giannaccare G, Versura P, Buzzi M, Primavera L, Pellegrini
M, Campos EC. Blood derived eye drops for the treatment of
cornea and ocular surface diseases. Transfus Apher Sci. (2017)
56:595–604. doi: 10.1016/j.transci.2017.07.023
10. Buzzi M, Versura P, Grigolo B, Cavallo C, Terzi A, Pellegrini M, et al.
Comparison of growth factor and interleukin content of adult peripheral
blood and cord blood serum eye drops for cornea and ocular surface diseases.
Transfus Apher Sci. (2018) 57:549–55. doi: 10.1016/j.transci.2018.06.001
11. Belderbos ME, Levy O, Meyaard L, Bont L. Plasma-mediated immune
suppression: a neonatal perspective. Pediatr Allergy Immunol. (2013) 24:102–
13. doi: 10.1111/pai.12023
12. Cox ST, Danby R, Hernandez D, Alejandro Madrigal J, Saudemont A.
Functional characterisation and analysis of the soluble NKG2D ligand
repertoire detected in umbilical cord blood plasma. Front Immunol. (2018)
9:1282. doi: 10.3389/fimmu.2018.01282
13. Cox S, Madrigal J, Saudemont A. Three novel allelic variants of
the RAET1E/ULBP4 gene in humans. Tissue Antigens. (2012) 80:390–
2. doi: 10.1111/j.1399-0039.2012.01933.x
14. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, et al.
Interactions of human NKG2D with its ligands MICA, MICB, and homologs
of the mouse RAE-1 protein family. Immunogenetics. (2001) 53:279–
87. doi: 10.1007/s002510100325
15. Versura P, Profazio V, Buzzi M, Stancari A, Arpinati M, Malavolta N, et al.
Efficacy of standardized and quality-controlled cord blood serum eye drop
therapy in the healing of severe corneal epithelial damage in dry eye. Cornea.
(2013) 32:412–8. doi: 10.1097/ICO.0b013e3182580762
16. Ljubimov A V., Saghizadeh M. Progress in corneal wound healing. Prog Retin
Eye Res. (2015) 49:17–45. doi: 10.1016/j.preteyeres.2015.07.002
Frontiers in Immunology | www.frontiersin.org 13 May 2020 | Volume 11 | Article 942
Samarkanova et al. CB-PRP Derivatives
17. Nagaraja S, Chen L, DiPietro LA, Reifman J, Mitrophanov AY. Computational
analysis identifies putative prognostic biomarkers of pathological scarring in
skin wounds. J Transl Med. (2018) 16:32. doi: 10.1186/s12967-018-1406-x
18. Fréchette J-P, Martineau I, Gagnon G. Platelet-rich plasmas: growth
factor content and roles in wound healing. J Dent Res. (2005) 84:434–
9. doi: 10.1177/154405910508400507
19. Sirchia G, Rebulla P, Mozzi F, Lecchi L, Lazzari L, Ratti I. A quality system for
placental blood banking. Bone Marrow Transplant. (1998) 21(Suppl. 3):S43–7.
20. Strandberg G, Sellberg F, Sommar P, Ronaghi M, Lubenow N, Knutson
F, et al. Standardizing the freeze-thaw preparation of growth factors
from platelet lysate. Transfusion. (2017) 57:1058–65. doi: 10.1111/trf.
13998
21. Cox ST, Hernandez D, Danby R, Turner TR, Madrigal JA. Diversity and
characterisation of polymorphic 3’ untranslated region haplotypes of MICA
and MICB genes. HLA. (2018) 92:392–402. doi: 10.1111/tan.13434
22. Cox ST, Laza-Briviesca R, Pearson H, Soria B, Gibson D, Gomez S, et al.
Umbilical cord blood plasma contains soluble NKG2D ligands that mediate
loss of natural killer cell function and cytotoxicity. Eur J Immunol. (2015)
45:2324–34. doi: 10.1002/eji.201444990
23. Baba K, Yamazaki Y, Sone Y, Sugimoto Y,Moriyama K, Sugimoto T, et al. An in
vitro long-term study of cryopreserved umbilical cord blood-derived platelet-
rich plasma containing growth factors—PDGF-BB, TGF-β and VEGF. J
Cranio Maxillofacial Surg. (2019) 47:668–75. doi: 10.1016/j.jcms.2019.01.020
24. Valentini C, Orlando N, Iachininoto M, Pinci P, Nuzzolo E, Teofili
L. Cord blood platelet lysate: in vitro evaluation to support the
use in regenerative medicine. Mediterr J Hematol Infect Dis. (2019)
11:e2019021. doi: 10.4084/mjhid.2019.021
25. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands
impair expression of NKG2D and T-cell activation. Nature. (2002) 419:734–
8. doi: 10.1038/nature01112
26. Cerboni C, Ardolino M, Santoni A, Zingoni A. Detuning CD8 + T
lymphocytes by down-regulation of the activating receptor NKG2D: Role
of NKG2D ligands released by activated T cells. Blood. (2009) 113:2955–
64. doi: 10.1182/blood-2008-06-165944
27. Okuda K, Kawase T, Momose M, Murata M, Saito Y, Suzuki H,
et al. Platelet-rich plasma contains high levels of platelet-derived growth
factor and transforming growth factor-β and modulates the proliferation
of periodontally related cells in vitro. J Periodontol. (2003) 74:849–
57. doi: 10.1902/jop.2003.74.6.849
28. Qian Y, Han Q, Chen W, Song J, Zhao X, Ouyang Y, et al.
Platelet-rich plasma derived growth factors contribute to stem cell
differentiation in musculoskeletal regeneration. Front Chem. (2017)
5:1–8. doi: 10.3389/fchem.2017.00089
29. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth
factor analysis from platelet-rich plasma: implications for wound healing.
Plast Reconstr Surg. (2004) 114:1502–8. doi: 10.1097/01.PRS.0000138251.07
040.51
30. Picardi A, Lanti A, Cudillo L, Cerretti R, Dentamaro T, De Angelis G, et al.
Platelet gel for treatment of mucocutaneous lesions related to graft-versus-
host disease after allogeneic hematopoietic stem cell transplant. Transfusion.
(2010) 50:501–6. doi: 10.1111/j.1537-2995.2009.02439.x
31. Everts PAM, Knape JTA, Weibrich G, Schönberger JPAM, Hoffmann J,
Overdevest EP, et al. Platelet-rich plasma and platelet gel: a review. J Extra
Corpor Technol. (2006) 38:174–87.
32. Javier Sánchez-González D, Méndez-Bolaina E, Trejo-Bahena NI.
Platelet-rich plasma peptides: key for regeneration. Int J Pept. (2012)
2012:532519. doi: 10.1155/2012/532519
33. Sorg H, Tilkorn DJ, Hager S, Hauser J, Mirastschijski U. Skin wound healing:
an update on the current knowledge and concepts. Eur Surg Res. (2017)
58:81–94. doi: 10.1159/000454919
34. MacLeod AS,Mansbridge JN. The innate immune system in acute and chronic
wounds. Adv Wound Care. (2015) 5:65–78. doi: 10.1089/wound.2014.0608
35. Barsotti MC, Chiara Barsotti M, Losi P, Briganti E, Sanguinetti
E, Magera A, et al. Effect of platelet lysate on human cells
involved in different phases of wound healing. PLoS ONE. (2013)
8:e84753. doi: 10.1371/journal.pone.0084753
36. Li TY, Wu YT, Chen LC, Cheng SN, Pan RY, Chen YC. An exploratory
comparison of single intra-articular injection of platelet-rich plasma vs.
hyaluronic acid in treatment of haemophilic arthropathy of the knee.
Haemophilia. (2019) 25:484–92. doi: 10.1111/hae.13711
37. Laver L, Marom N, Dnyanesh L, Mei-Dan O, Espregueira-Mendes J, Gobbi A.
PRP for degenerative cartilage disease: a systematic review of clinical studies.
Cartilage. (2017) 8:341–64. doi: 10.1177/1947603516670709
38. Nugent RB, Lee GA. Ophthalmic use of blood-derived products. Surv
Ophthalmol. (2015) 60:406–34. doi: 10.1016/j.survophthal.2015.03.003
39. Rodríguez-Pomar C, Pintor J, Colligris B, Carracedo G. Therapeutic inhibitors
for the treatment of dry eye syndrome. Expert Opin Pharmacother. (2017)
18:1855–65. doi: 10.1080/14656566.2017.1403584
40. Lee JH, Kim MJ, Ha SW, Kim HK. Autologous platelet-rich plasma eye drops
in the treatment of recurrent corneal erosions. Kor J Ophthalmol. (2016)
30:101–7. doi: 10.3341/kjo.2016.30.2.101
41. Alio JL, Rodriguez AE, Abdelghany AA, Oliveira RF. Autologous platelet-
rich plasma eye drops for the treatment of post-LASIK chronic ocular surface
syndrome. J Ophthalmol. (2017) 2017:1–6. doi: 10.1155/2017/2457620
42. Zhang X, Volpe EA, Gandhi NB, Schaumburg CS, Siemasko KF, Pangelinan
SB, et al. NK cells promote Th-17 mediated corneal barrier disruption in dry
eye. PLoS ONE. (2012) 7:1–10. doi: 10.1371/journal.pone.0036822
43. Chen Y, Chauhan SK, Saban DR, Sadrai Z, Okanobo A, Dana R. Interferon-γ-
secreting NK cells promote induction of dry eye disease. J Leukoc Biol. (2011)
89:965–72. doi: 10.1189/jlb.1110611
44. Allwood MC. The influence of light on vitamin A
degradation during administration. Clin Nutr. (1982) 1:63–
70. doi: 10.1016/0261-5614(82)90006-1
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
The reviewer JB declared a past co-authorship with one of the authors SQ
to the handling editor.
Copyright © 2020 Samarkanova, Cox, Hernandez, Rodriguez, Casaroli-Marano,
Madrigal and Querol. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 14 May 2020 | Volume 11 | Article 942
